Cognition Therapeutics Inc (CGTX) — Institutional Holders Breakdown (Q2 2026)

CGTX ranks #5475 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CGTX is a top-conviction position for BIOS Capital Management, LP — at 16.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

CGTX is down 0.4% today, but institutions show net buying of $2.3M this quarter — a divergence between today's price move and the underlying institutional flow.

CGTX reported a net loss of $23.5M in its latest fiscal year.

• Not yet profitable — net loss of $23.5M in the latest fiscal year
• Net income improved year over year, from -$34.0M to -$23.5M
• Operating cash flow was negative, using $24.6M in cash
• Current ratio of 3.45x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.41x equity — within a conventional range